Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EBITDA (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed EBITDA for 3 consecutive years, with -$3.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBITDA rose 7.27% year-over-year to -$3.6 million, compared with a TTM value of -$12.8 million through Dec 2024, up 18.95%, and an annual FY2024 reading of -$12.8 million, up 18.95% over the prior year.
  • EBITDA was -$3.6 million for Q4 2024 at Oramed Pharmaceuticals, down from -$3.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.9 million in Q3 2023 and bottomed at -$12.3 million in Q4 2022.
  • Average EBITDA over 3 years is -$6.0 million, with a median of -$3.8 million recorded in 2023.
  • The sharpest move saw EBITDA surged 68.55% in 2023, then dropped 6.77% in 2024.
  • Year by year, EBITDA stood at -$12.3 million in 2022, then soared by 68.55% to -$3.9 million in 2023, then rose by 7.27% to -$3.6 million in 2024.
  • Business Quant data shows EBITDA for ORMP at -$3.6 million in Q4 2024, -$3.1 million in Q3 2024, and -$3.1 million in Q2 2024.